Business
Exscientia and SRI International collaborate
Exscientia and SRI International collaborate.
About this update from Frontier Ip Group Plc
[{"type":"text","content":"\n \n \n RNS Number : 1823M\n Frontier IP Group plc\n 07 May 2020\n \n \n \n \n RNS Reach\n \n \n AIM: FIPP\n \n \n 07 May 2020\n \n \n \n \n \n \n \n \n Frontier IP Group plc\n \n \n (\"Frontier IP\" or the \"Group\")\n \n \n \n \n \n Portfolio news - Exscientia and SRI International enter collaboration to accelerate drug discovery through automation and artificial intelligence \n \n \n \n \n \n Frontier IP, a specialist in commercialising intellectual property, notes that portfolio company Exscientia (\"Exscientia\" or the \"Company\"), a world leader in AI-driven drug discovery, has entered into a collaboration with US research centre SRI International (\"SRI\") to expedite discovery of selective molecules for a high value oncology target. \n \n \n \n \n \n The collaboration will see the two companies implement a new approach to drug discovery by integrating SRI's fully automated synthetic-chemistry system with Exscientia's Centaur ChemistTM system. \n \n \n \n \n \n Frontier IP's holds a 3.3 per cent equity stake in Exscientia. \n \n \n \n \n \n Exscientia statement in full:\n \n \n \n \n \n \n \n \n SRI International and Exscientia Enter Collaboration to Accelerate Drug Discovery Through Automation and Artificial Intelligence.\n \n \n \n \n \n Companies will combine SynFini and Centaur Chemist platforms to focus on small-molecule oncology target\n \n \n \n \n \n MENLO PARK, Calif. and OXFORD, United Kingdom. \n \n \n \n \n \n Exscientia, a clinical-stage Artificial Intelligence (AI) drug-discovery company and SRI International (SRI), a research center headquartered in Menlo Park, California announced today that the companies have entered into a drug-discovery collaboration agreement to implement a new approach to drug discovery by integrating AI design with automated compound synthesis. \n \n \n \n \n \n Through the collaboration, the companies will combine SRI's fully automated SynFini™ synthetic-chemistry system with Exscientia's Centaur Chemist™ AI platform to expedite discovery of selective molecules for a high value oncology target.\n \n \n \n \n \n \"Both the SynFini and Centaur Chemist platforms have demonstrated ability to overcome key drug discovery challenges,\" said Nathan Collins, Ph.D., chief strategy officer of SRI'...